Discovery and development of sGC stimulators for the treatment of pulmonary hypertension and rare diseases-Reference-Cited by-同舟云学术

Discovery and development of sGC stimulators for the treatment of pulmonary hypertension and rare diseases

Published:2018-07 Issue: Volume:77 Page:88-95
ISSN:1089-8603
Container-title:Nitric Oxide
language:en
Short-container-title:Nitric Oxide

Author:

Sandner Peter,Becker-Pelster Eva-Maria,Stasch Johannes Peter

Publisher

Elsevier BV

Subject

Cancer Research,Clinical Biochemistry,Physiology,Biochemistry

Reference84 articles.

1. Antiinflammatory activity of soluble guanylate cyclase: cGMP-dependent down-regulation of P-selectin expression and leukocyte recruitment;Ahluwalia;Proc. Natl. Acad. Sci. U. S. A.,2004

2. Chronic intratracheal application of the soluble guanylyl cyclase stimulator BAY 41-8543 ameliorates experimental pulmonary hypertension;Amirjanians;Oncotarget.,2017

3. BAY41–2272 Attenuates Pulmonary Arteries Hypertrophy in a Rodent Model of Chronic Thromboembolic Pulmonary Hypertension Hämostaseologie 1a;Arias Loza,2016

4. Pulmonary and systemic vasodilator responses to the soluble guanylyl cyclase stimulator, BAY 41–8543, are modulated by nitric oxide;Badejo;Am. J. Physiol. Heart Circ. Physiol.,2010

5. Pulmonary hypertension in patients with chronic obstructive pulmonary disease. Advances in pathophysiology and management;Barberà;Drugs,2009

Cited by 31 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The nitric oxide–soluble guanylate cyclase–cGMP pathway in pulmonary hypertension: from PDE5 to soluble guanylate cyclase;European Respiratory Review;2024-01-31

2. Decoding signaling mechanisms: unraveling the targets of guanylate cyclase agonists in cardiovascular and digestive diseases;Frontiers in Pharmacology;2023-12-20

3. Mesenchymal stem cell-based therapy for autoimmune-related fibrotic skin diseases—systemic sclerosis and sclerodermatous graft-versus-host disease;Stem Cell Research & Therapy;2023-12-18

4. Advances in targeted therapy for pulmonary arterial hypertension in children;European Journal of Pediatrics;2022-12-17

5. Inhaled mosliciguat (BAY 1237592): targeting pulmonary vasculature via activating apo-sGC;Respiratory Research;2022-10-01